Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer

Publication
Video
Special ReportsNSCLC (Issue 10)
Volume 10
Issue 10

Geoffrey R. Oxnard, MD, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.

Geoffrey R. Oxnard, MD, Assistant Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute, discusses resistance to EGFR inhibitors in patients with lung cancer. Oxnard says resistance to treatment in lung cancer is complex, in that it can change from day to day. He cites one example as patients possibly being resistant to T790M targeted treatments to possibly a MET-related resistance.

Articles in this issue
Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC
Dr. Renato G. Martins on Nivolumab and its Role as a Second-Line Treatment in NSCLC
Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer
Dr. Geoffrey R. Oxnard Treating EGFR-Inhibitor Resistant Patients With Lung Cancer
Marianne Davies, NP, on Assessing Immunotherapy Toxicities in Lung Cancer Patients
Marianne Davies, NP, on Assessing Immunotherapy Toxicities in Lung Cancer Patients
Research Team Challenges Plant-Derived Molecule for the Treatment of NSCLC
Research Team Challenges Plant-Derived Molecule for the Treatment of NSCLC
Combining Immunotherapy With Anti-VEGF Agents Rigorously Explored in NSCLC
Combining Immunotherapy With Anti-VEGF Agents Rigorously Explored in NSCLC
Lung Cancer Research Shows Distinct Genomic Differences in Younger Patients
Lung Cancer Research Shows Distinct Genomic Differences in Younger Patients
Lung Cancer Incidence and Mortality Review Shows No Ethnic Differences in Women
Lung Cancer Incidence and Mortality Review Shows No Ethnic Differences in Women
NSCLC Study Shows Surprising Association Between Reduced Endocytic Activity and Metastases
NSCLC Study Shows Surprising Association Between Reduced Endocytic Activity and Metastases
Related Videos
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Edward B. Garon, MD, MS, and Anne S. Tsao, MD, experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Experts on lung cancer
Related Content
FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy

November 29th 2023
Article

A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.

Read More

Strategies for Neoadjuvant NSCLC Treatment

Strategies for Neoadjuvant NSCLC Treatment

September 1st 2023
Podcast

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

Listen

Debating Issues in Frontline Treatment Approach for Advanced HCC

Debating Issues in Frontline Treatment Approach for Advanced HCC

November 29th 2023
Article

At 2 separate Case-Based Roundtable events, oncologists discussed important factors that could influence their choice of frontline therapy for a patient with advanced hepatocellular carcinoma.

Read More

Therapies on the Horizon in EGFR Exon 20–Positive Lung Cancer

Therapies on the Horizon in EGFR Exon 20–Positive Lung Cancer

January 15th 2021
Podcast

In season 2, episode 1 of Targeted Talks, Nagashree Seetharamu, MD, led a conversation with Luis E. Raez, MD, about the evolving treatment landscape for EGFR exon 20–mutated lung cancer.

Listen

Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens

Interpreting Trial Data on Tolerability in Third-Line mRCC Regimens

November 28th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, and participants discussed dosing and toxicity issues related to tivozanib and lenvatinib/everolimus in a patient who has received 2 prior lines of therapy for metastatic clear cell renal cell carcinoma.

Read More

KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC

KRAS G12C Inhibitors Show Promise as Second-Line Treatment of NSCLC

November 27th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Devika Das, MD, discussed the role of KRAS inhibitors and the outcome of the KRYSTAL-1 trial in patients with non–small cell lung cancer. This is the first of 2 articles based on this event.

Read More